This Is What Whales Are Betting On Regeneron Pharmaceuticals
Portfolio Pulse from Benzinga Insights
A significant investor has taken a bearish stance on Regeneron Pharmaceuticals (NASDAQ:REGN), with 90% of recent trades reflecting bearish expectations. The targeted price range for Regeneron over the last 3 months is $700.0 to $900.0. Despite this, several financial institutions including Guggenheim, Oppenheimer, RBC Capital, Barclays, and Morgan Stanley have maintained positive ratings on Regeneron, with price targets ranging from $820 to $950.
August 14, 2023 | 5:46 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Regeneron Pharmaceuticals has seen a bearish stance from a significant investor, with 90% of recent trades being bearish. However, several financial institutions have maintained positive ratings on the company.
The bearish stance from a significant investor could potentially drive the stock price down in the short term. However, the positive ratings from several financial institutions could counteract this effect to some extent.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100